Andrew Hore – Quoted Micro 19 April 2021

AQUIS STOCK EXCHANGE NFT Investments (NFT) is a shell that intends to invest a portfolio of non-fungible tokens (NFTs). An NFT is a digital file with a unique and verified identity held on a digital ledger or blockchain. The tokens can be bought with cryptocurrency and resold. Ownership of NFTs can be tracked and they […]

Alan Green talks Coinbase & Mast Energy #MAST IPOs and markets, plus ECR Minerals #ECR, Blencowe Resources #BRES & Open Orphan #ORPH on UK Investor Magazine podcast

Alan Green joins the UK Investor Magazine Podcast as we await trading in Coinbase, the cryptocurrency dealing platform which could be valued at $100bn. The Coinbase IPO marks the move of cryptocurrencies to the mainstream and we question what it could mean for assets such as Bitcoin if investors view Coinbase’s listing as a ‘buy […]

Open Orphan #ORPH – Potential demerger of certain non-core assets

Open Orphan plc ((AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials,announces that it is at an advanced stage in planning for a possible spin-out of certain non-core Development IP Assets. These Development IP Assets are a portfoilio […]

Open Orphan #ORPH – Launch of Disease in Motion platform

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO , a subsidiary of Open Orphan, has officially launched its Disease in Motion® platform. This unique data-focused platform includes clinical, immunological, virological and digital […]

Open Orphan #ORPH – £7.5m Human Challenge Study Contract

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO , a subsidiary of Open Orphan, has entered into a contract with a  biotechnology company to run a human viral challenge study for a […]

Open Orphan #ORPH – COVID-19 Human Challenge Programme update

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces an update in the world’s first COVID-19 characterisation study. Following Research Ethics Committee approval on 17 February 2021, hVIVO, a subsidiary of Open Orphan, began the […]

Open Orphan #ORPH – Journal for Clinical Studies article publication

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces that an article has been written and published in the Journal for Clinical Studies (“JCS”). The article, entitled “Hot Topics – Vaccine Solutions for Tropical Diseases” is written […]

Open Orphan #ORPH – New contract win with Oxford BioTherapeutics

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its subsidiary Venn Life Sciences (“Venn”) has been awarded a contract for a study with Oxford BioTherapeutics, a clinical stage oncology company with a pipeline of immune-oncology and antibody-drug […]